United States Diabetes Drugs Market is expected to reach US$ 80 Billion by 2033 | Top Companies - Eli Lilly and Company, Novo Nordisk, Merck & Co., Inc.

Market Size and Growth:

The Global Diabetes Drugs Market size reached US$ 80.75 Billion in 2024 from US$ 67.16 Billion in 2023 and is expected to reach US$ 178.01 Billion by 2033, growing at a CAGR of 9.3% during the forecast period 2025-2033. The Market is growing due to the rising prevalence of diabetes worldwide and increasing adoption of advanced drug therapies for better disease management. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/diabetes-drugs-market?sz

The Diabetes Drugs Market encompasses the global industry involved in the research, development, manufacturing, and sale of pharmaceutical products used to manage and treat diabetes. It includes insulin therapies, oral hypoglycemic agents, GLP-1 receptor agonists, SGLT2 inhibitors, and other innovative treatments, catering to type 1, type 2, and gestational diabetes patients, driven by rising prevalence and healthcare advancements.

Industry Recent Developments: United States

✅ August 2025: Teva Pharmaceuticals received FDA approval for the first generic version of liraglutide injection, a GLP-1 drug used for weight loss.

✅ August 2025: Sales of Novo Nordisk's diabetes drugs, including Ozempic, slowed due to competition from Eli Lilly's Mounjaro and generic drug makers.

✅ October 2025: Medicare expanded continuous glucose monitor (CGM) coverage, improving access particularly for type-2 diabetes patients who previously relied on finger-stick tests. Also, Dexcom's G7 15-day CGM system received FDA clearance, offering extended wear convenience.

Industry Recent Developments: Japan

✅ September 2025: Takeda Pharmaceutical expanded its digital therapeutics initiatives by launching a virtual coaching program for diabetes, integrating telemedicine and AI-based treatment optimization to improve adherence and clinical outcomes.

✅ October 2025: Fujitsu Limited introduced a mobile-based digital therapeutic app for diabetes management giving real-time feedback, insulin guidance, and lifestyle recommendations to patients.

✅ August 2025: Hitachi launched a connected device ecosystem for diabetes care, representing a commitment to advanced diabetes technologies in Japan.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/diabetes-drugs-market?sz

FDA Approvals / Regulatory Milestones in (2025):

✅ In January 2025, the FDA approved semaglutide (Ozempic) for reducing the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes + chronic kidney disease.

✅ In February 2025, the FDA approved Merilog (insulin aspart-szjj), a rapid-acting insulin biosimilar to NovoLog, for adults and pediatric diabetes patients.

✅ In July 2025, the FDA approved Kirsty (insulin aspart-xjhz) from Biocon Biologics. It is the first interchangeable rapid-acting insulin aspart biosimilar for the U.S. market.

✅ The FDA also approved generic sitagliptin + metformin XR (Janumet XR) in 2025, improving access to a commonly used diabetes combination therapy.

✅ The FDA declared that prior shortages of popular GLP‐1 diabetes / obesity medications (like Ozempic, Wegovy, Mounjaro) have been resolved.

Mergers, Licensing & Strategic Deals in (2025):

✅ Roche and Zealand Pharma struck a co-development & licensing deal (up to US$ 5.3 billion) for petrelintide, a long-acting amylin analog. They plan to commercialize it both as monotherapy and in a fixed‐dose combo with Roche's CT‐388 (a GLP-1/GIP candidate).

✅ Biocon Biologics expanded its collaboration with Civica, Inc. (a U.S. non-profit) to manufacture and supply insulin glargine for the U.S. market under a private-label arrangement, improving access to affordable long-acting insulin.

✅ Earlier in 2025, Biocon Biologics had also tied up with Civica to produce insulin aspart (rapid‐acting) at Civica's U.S. facility, to improve availability.

Major Key Players:

1. Eli Lilly and Company - A global pharmaceutical leader, specializing in diabetes care, oncology, and immunology, known for innovative drug development.

2. Novo Nordisk - A Danish company focused on diabetes, obesity, and rare diseases, recognized for its insulin and GLP-1 therapies.

3. Merck & Co., Inc. - A leading U.S.-based pharma firm with a strong portfolio in oncology, vaccines, and infectious diseases.

4. Boehringer Ingelheim Pharmaceuticals, Inc. - German-based company focusing on respiratory, cardiovascular, and metabolic diseases with innovative R&D.

5. Sanofi - A French multinational specializing in diabetes, cardiovascular, oncology, and vaccines, with a strong global presence.

6. AstraZeneca - UK-Swedish pharma company excelling in oncology, cardiovascular, respiratory, and immunology therapeutics worldwide.

Segments Covered in the Diabetes Drugs Market:

By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP-4 Inhibitors, SGLT2 Inhibitors, Biguanides (Metformin), Thiazolidinediones, Meglitinides, Alpha-glucosidase Inhibitors.

By Diabetes Type: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes.

By Route of Administration: Oral, Parenteral.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Diabetes Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=diabetes-drugs-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Diabetes Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Diabetes Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Diabetes Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Diabetes Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Diabetes Drugs market?

➠ Who are the global key manufacturers of the Diabetes Drugs Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Diabetes Drugs market opportunities and threats faced by the vendors in the global Diabetes Drugs Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Diabetes Drugs market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.